Brief: Novo Says Ozempic Cuts Risk Of Major Cardiovascular Events
29/09/2026 15:13
BRIEF-Novo Says Ozempic Cuts Risk Of Major Cardiovascular Events Sept 29 (Reuters) - Novo Nordisk A/S NOVOb.CO:
NOVO'S OZEMPIC (SEMAGLUTIDE) 2 MG ASSOCIATED WITH LOWER RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (DEATH, HEART ATTACK, AND STROKE) IN ADULTS WITH TYPE 2 DIABETES COMPARED TO SWITCHING TO MOUNJARO (TIRZEPATIDE), IN REAL-WORLD ANALYSIS AT EASD
SEMAGLUTIDE 2 MG DOSE ESCALATION LINKED TO 6% LOWER RISK OF MAJOR CARDIOVASCULAR EVENTS
OZEMPIC 2 MG ASSOCIATED WITH LOWER RISK OF MAJOR CARDIOVASCULAR EVENTS VERSUS MOUNJARO
Source text: ID:nPnSjH8ka
Further company coverage: [NOVOb.CO]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Novo Nordisk A/S
See all newsTrial failures of Novartis, Novo Nordisk heart drugs leave experts guessing
Brief: Novo Real-World Studies Link Wegovy 2.4 MG To Reductions In Liver Enzymes, Weight, Blood Sugar In Adults With Mash
Lilly to sell obesity drugs directly on Hims & Hers site (updated)
Lilly to sell obesity drugs directly on Hims & Hers site
Brief: Executive Martin Holst Lange Sold Novo Shares Worth DKK 3.4 Mln